RxDoctor Payments Data

Michelle Ovando, PA

Medical · Tinley Park, ILNPI 1760676969

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 241 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,677, 9.1 times the $185 reported in 2021.

$5,530in general payments, 2019–2025

Across 241 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Regeneron Healthcare Solutions, Inc.$588
  • Novartis$499
  • Lilly USA, LLC$416
  • Sun Pharmaceutical Industries Inc.$408
  • Sanofi$401
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$5,36997%
  • Education$1613%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,530 in reported general payments places this provider in the 85th percentile of 449 medical providers in Illinois.

See all medical providers in Illinois

Medicare billing

Part B allowed, 2024
$274,144
Medicare patients
1,248
Services billed
4,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa22$451,829
Dupixent PenDupilumab67$297,503
Humira(Cf) PenAdalimumab13$124,747
Taltz AutoinjectorIxekizumab17$109,658
OtezlaApremilast13$64,053
Clobetasol Propionate155$11,037
Ketoconazole390$6,149
Calcipotriene30$6,030
Desonide43$4,999
Betamethasone Dipropionate119$4,967
Tacrolimus24$4,589
Tretinoin36$3,791
Triamcinolone Acetonide308$3,413
Metronidazole74$3,277
Fluocinonide67$3,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$196$64,05313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 449 medical providers in Illinois.

Other medical in Tinley Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →